Menu

Anti-CRISPR Proteins Found that Block Cas12a Nuclease

Using bioinformatics, two teams of scientists identified inhibitory proteins for Cas9’s relative.

Sep 6, 2018
Ashley Yeager

ABOVE: Inhibitors of Cas9, illustrated here, had been found previously.
© ISTOCK, MOLEKUUL

Newly identified anti-CRISPR proteins block Cas12a, a cousin of the Cas9 nuclease, both of which are widely used in genome editing, two teams of researchers report today (September 6) in Science. While past studies have identified several inhibitors of Cas9, these proteins are the first ones known to act against Cas12a. 

Both teams used bioinformatics tools to scan bacterial genomes for Cas inhibitors and came across several candidate proteins, which the researchers then tested in human cells. One of the proteins, AcrVA1, emerged as the most effective at countering Cas12a, suggesting it could become another tool to keep CRISPR gene editing in check, the scientists say.

See “CRISPR Antidotes Galore” and “Anti-CRISPR Protein Reduces Off-Target Effects

“The strategy described herein enabled the identification of many widespread anti-CRISPR proteins, which may prove useful in future anti-CRISPR discovery,” coauthor Nicole Marino of the University of California, San Francisco, and her colleagues write in their report.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.